Active substance
Atorvastatin
- SFDA 67
- US FDA 35
- Health Canada 87
- US price lines 9
- NHS prices 9
- WHO EML 1
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ASTATIN 10MG F.C TABLETS | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ASTATIN 20MG F.C TABLETS | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ASTATIN 40MG F.C TABLETS | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 86.90 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ATORLIP 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | GLOBAL PHARMA | Valid |
| ATORLIP 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | GLOBAL PHARMA | Valid |
| ATORLIP 40 mg film-coated tablet | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 86.90 | Generic · Prescription | GLOBAL PHARMA | Valid |
| ATORVA 10MG F.C. TABLETS | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ATORVA 10MG F.C. TABLETS | 10 mg | Film-coated tablet · Oral use | 500 Blister | SAR 724.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ATORVA 20MG F.C. TABLETS | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ATORVA 20MG F.C. TABLETS | 20 mg | Film-coated tablet · Oral use | 500 Blister | SAR 724.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ATORVA 40MG F.C. TABLETS | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 86.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ATORVA 40MG F.C. TABLETS | 40 mg | Film-coated tablet · Oral use | 500 Blister | SAR 1448.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ATORVA 80MG F.C. TABLETS | 80 mg | Film-coated tablet · Oral use | 30 Blister | SAR 86.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ATORVA 80MG F.C. TABLETS | 80 mg | Film-coated tablet · Oral use | 500 Blister | SAR 1448.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Atorva | 10 mg | Film-coated tablet · Oral use | 130 Blister | SAR 172.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Atorva | 40 mg | Film-coated tablet · Oral use | 110 Blister | SAR 304.80 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Atorva | 20 mg | Film-coated tablet · Oral use | 130 Blister | SAR 172.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Aztolyp | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 86.90 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| Aztolyp | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| Aztolyp | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| LD-NOR 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | Cooper Pharma Arabia | Valid |
| LD-NOR 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | Cooper Pharma Arabia | Valid |
| LD-NOR 40 mg film-coated tablet | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 86.90 | Generic · Prescription | Cooper Pharma Arabia | Valid |
| LIPICURE 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | DAMMAM PHARMA | Valid |
| LIPICURE 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 43.45 | Generic · Prescription | DAMMAM PHARMA | Valid |
42 more — full table
Indications — CHI Daman Drug Formulary
ANTIPHOSPHOLIPID SYNDROME; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); RAYNAUD'S PHENOMENON; RENAL TRANSPLANT; ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LIPITOR | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | UPJOHN | Prescription | 17 Dec 1996 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | CHARTWELL RX | Prescription | 29 May 2012 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | APOTEX INC | Prescription | 29 May 2012 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | MYLAN PHARMS INC | Prescription | 29 May 2012 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | DR REDDYS LABS LTD | Prescription | 17 Jul 2012 |
| ATORVASTATIN CALCIUM | EQ 80MG BASE | tablet · oral | DR REDDYS LABS LTD | Prescription | 17 Jul 2012 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | LANNETT CO INC | Prescription | 5 Apr 2013 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | SCIEGEN PHARMS | Prescription | 19 May 2016 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | TEVA PHARMS USA | Prescription | 27 Mar 2017 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | ACCORD HLTHCARE | Prescription | 30 Mar 2018 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | GRAVITI PHARMS | Prescription | 18 Jun 2018 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | ZYDUS PHARMS | Prescription | 20 Nov 2018 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | ALKEM LABS LTD | Prescription | 21 Dec 2018 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | MSN | Prescription | 8 Feb 2019 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | UMEDICA | Prescription | 19 Aug 2020 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | DR REDDYS | Prescription | 14 Jul 2021 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | APOTEX | Prescription | 2 Sep 2021 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | BIOCON PHARMA | Prescription | 23 Nov 2022 |
| ATORVALIQ | 20MG/5ML | suspension · oral | CMP DEV LLC | Prescription | 1 Feb 2023 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | HETERO LABS LTD V | Prescription | 12 Sep 2023 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | MANKIND PHARMA | Prescription | 5 Jan 2024 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | LAURUS | Prescription | 22 Jan 2024 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | SHANDONG XINHUA | Prescription | 25 Jan 2024 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 13 Feb 2024 |
| ATORVASTATIN CALCIUM | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE; EQ 80MG BASE | tablet · oral | MACLEODS PHARMS | Prescription | 3 Jun 2024 |
10 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACH-ATORVASTATIN CALCIUM | 02457741 | 10 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| ACH-ATORVASTATIN CALCIUM | 02457768 | 20 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| ACH-ATORVASTATIN CALCIUM | 02457776 | 40 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| ACH-ATORVASTATIN CALCIUM | 02457784 | 80 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| AG-ATORVASTATIN | 02506076 | 10 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-ATORVASTATIN | 02506084 | 20 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-ATORVASTATIN | 02506092 | 40 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-ATORVASTATIN | 02506106 | 80 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-ATORVASTATIN | 02295261 | 10 MG | TABLET · ORAL | APOTEX INC |
| APO-ATORVASTATIN | 02295288 | 20 MG | TABLET · ORAL | APOTEX INC |
| APO-ATORVASTATIN | 02295296 | 40 MG | TABLET · ORAL | APOTEX INC |
| APO-ATORVASTATIN | 02295318 | 80 MG | TABLET · ORAL | APOTEX INC |
| ATORVASTATIN | 02348705 | 10 MG | TABLET · ORAL | SANIS HEALTH INC |
| ATORVASTATIN | 02348713 | 20 MG | TABLET · ORAL | SANIS HEALTH INC |
| ATORVASTATIN | 02348721 | 40 MG | TABLET · ORAL | SANIS HEALTH INC |
| ATORVASTATIN | 02348748 | 80 MG | TABLET · ORAL | SANIS HEALTH INC |
| ATORVASTATIN | 02545462 | 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ATORVASTATIN | 02545470 | 20 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ATORVASTATIN | 02545489 | 40 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ATORVASTATIN | 02545497 | 80 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ATORVASTATIN-10 | 02411350 | 10 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| ATORVASTATIN-20 | 02411369 | 20 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| ATORVASTATIN-40 | 02411377 | 40 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| ATORVASTATIN-80 | 02411385 | 80 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| AURO-ATORVASTATIN | 02407256 | 10 MG | TABLET · ORAL | AURO PHARMA INC |
62 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ATORVALIQ 20 MG/5 ML SUSP | $1.23479 | per ML | 1 Oct 2026 |
| US NADAC | ATORVASTATIN 10 MG TABLET | $0.02283 | per EA | 7 Oct 2026 |
| US NADAC | ATORVASTATIN 20 MG TABLET | $0.02792 | per EA | 7 Oct 2026 |
| US NADAC | ATORVASTATIN 40 MG TABLET | $0.03743 | per EA | 30 Sep 2026 |
| US NADAC | ATORVASTATIN 80 MG TABLET | $0.06926 | per EA | 7 Oct 2026 |
| US NADAC | LIPITOR 10 MG TABLET | $13.40831 | per EA | 23 Sep 2026 |
| US NADAC | LIPITOR 20 MG TABLET | $19.07256 | per EA | 23 Sep 2026 |
| US NADAC | LIPITOR 40 MG TABLET | $19.11383 | per EA | 23 Sep 2026 |
| US NADAC | LIPITOR 80 MG TABLET | $19.00394 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Atorvastatin 10mg chewable tablets sugar free | £13.80 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Atorvastatin 10mg tablets | £0.67 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Atorvastatin 20mg chewable tablets sugar free | £26.40 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Atorvastatin 20mg tablets | £0.83 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Atorvastatin 20mg/5ml oral suspension sugar free | £242.24 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Atorvastatin 30mg tablets | £2.94 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Atorvastatin 40mg tablets | £0.97 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Atorvastatin 60mg tablets | £4.85 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Atorvastatin 80mg tablets | £1.45 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.6. Lipid-lowering agents · core
Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia; Therapeutic equivalent to simvastatin for Coronary atherosclerosis
Safety signals and safety-related labeling changes
- US FDA 4 Nov 2024 CADUET — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Oct 2024 LIPTRUZET — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Apr 2024 ATORVALIQ — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 2 Apr 2024 LIPITOR — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Atorvastatin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.